From: The future of cancer immunotherapy for brain tumors: a collaborative workshop
Antigen target | Cellular product | Key inclusion | NCT number |
---|---|---|---|
GD2 | CAR-T | H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG) | NCT04196413 |
GD2 | CAR-T + C7R | high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) or medulloblastoma or another rare brain cancer that expresses GD2 | NCT04099797 |
B7-H3 | CAR-T | CNS disease for which there is no standard therapy, or diagnosis of DIPG or DMG at any time point following completion of standard therapy | NCT04185038 |
IL-13Ra2 | CAR-T | Recurrent/Refractory Malignant Brain Tumors | NCT04510051 |
Her2 | CAR-T | recurrent or refractory HER2-positive CNS tumors | NCT03500991 |
Her2 | CAR-T | progressive recurrent or refractory HER2-positive primary central nervous system (CNS) tumor or HER2 positive tumor metastatic to the CNS | NCT02442297 |
EGFR 806 | CAR-T | children and young adults with recurrent or refractory EGFR-positive CNS tumors | NCT03638167 |